Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 394 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Advanced Esophageal Cancer Clear all

Conditions: Esophageal Cancer
Interventions: gefitinib; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 119
States / cities: Mobile, Alabama • Jacksonville, Florida • Aurora, Illinois + 77 more

Conditions: Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Esophageal Cancer, Recurrent Gastric Cancer, Squamous Cell Carcinoma of the Esophagus, Stage III Esophageal Cancer, Stage IIIA Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer
Interventions: oblimersen sodium, cisplatin, fluorouracil; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 19 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma, Metastatic Gastric Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Esophageal Cancer, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastric Carcinoma, Unresectable Esophageal Cancer, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Carcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
Interventions: AgenT-797, Botensilimab, Balstilimab, Ramucirumab, Paclitaxel; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Carcinoma, SMARCA4 Mutation, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Squamous Cell Carcinoma
Interventions: PRT7732; Drug
Lead sponsor: Prelude Therapeutics Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 11
States / cities: San Francisco, California • Detroit, Michigan • New York, New York + 7 more

Conditions: Esophageal Cancer, Gastric Cancer
Interventions: irinotecan hydrochloride; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2004
U.S. locations: 18
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 15 more

Conditions: Esophageal Cancer
Interventions: cisplatin, Pemetrexed, radiation therapy; Drug · Radiation
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 120 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Esophageal Cancer
Interventions: bevacizumab, cisplatin, irinotecan hydrochloride, proteomic profiling, diagnostic laboratory biomarker analysis, mass spectrometry, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, radiation therapy; Biological · Drug · Genetic + 3 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Colorectal Cancer, Advanced Pancreatic Ductal Adenocarcinoma, Advanced Gastric Cancer, Advanced Gastroesophageal Junction Cancer, Advanced Esophageal Adenocarcinoma
Interventions: BGB-53038, Tislelizumab, Cetuximab; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 4
States / cities: Los Angeles, California • Kansas City, Kansas • Baltimore, Maryland + 1 more

Conditions: Pancreatic Cancer, Small Bowel Cancer, Colorectal Cancer, Melanoma, Non Small Cell Lung Cancer, Thyroid Cancer, Bladder Cancer, Head and Neck Cancer, Gastric Cancer, Esophageal Cancer, Cholangiocarcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Glioblastoma, MAPK Gene Mutation, KRAS Activating Mutation, BRAF Gene Mutation, NRAS Gene Mutation, HRAS Gene Mutation, MEK Mutation, ERK Mutation
Interventions: Ulixertinib (BVD-523); Drug
Lead sponsor: xCures; Industry
Eligibility: 12 Years and older
U.S. locations: 26
States / cities: Mobile, Alabama • Arroyo Grande, California • Newport Beach, California + 19 more

Conditions: Cancer
Interventions: capecitabine, irinotecan hydrochloride; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Cancer
Interventions: Panitumumab; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Cancer of the Esophagus
Interventions: Panitumumab, Capecitabine, Oxaliplatin, Radiation Therapy (RT); Drug · Radiation
Lead sponsor: Brian Czito; Other
Eligibility: 18 Years to 82 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Esophageal Cancer
Interventions: Everolimus, LDE 225; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Esophageal Cancer
Interventions: cisplatin, docetaxel, irinotecan hydrochloride, radiation therapy; Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Gastric Cancer, Stomach Cancer, Esophageal Cancer
Interventions: Margetuximab 10 mg/kg, Margetuximab 15 mg, Pembrolizumab; Biological
Lead sponsor: MacroGenics; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 11
States / cities: New Haven, Connecticut • Washington D.C., District of Columbia • Chicago, Illinois + 8 more

Conditions: Esophageal Cancer, Gastric Cancer
Interventions: cisplatin, epirubicin hydrochloride, fluorouracil, oxaliplatin, adjuvant therapy, neoadjuvant therapy; Drug · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
Interventions: ASP546C; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 31
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 28 more

Conditions: Esophageal Cancer, Gastric Cancer
Interventions: cisplatin, irinotecan hydrochloride; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2001
U.S. locations: 1
States / cities: New York, New York

Conditions: Melanoma, Breast Cancer, Merkel Cell Carcinoma, Squamous Cell Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Urothelial Carcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Small-cell Lung Cancer, Microsatellite Instability High, Gastric Cancer, Esophageal Cancer
Interventions: Echopulse, Poly ICLC, Standard of Care PD-1 Therapy; Device · Drug
Lead sponsor: Craig L Slingluff, Jr; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Gastric Cancer
Interventions: Rilotumumab, Placebo, Epirubicin, Cisplatin, Capecitabine; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 16
States / cities: Tucson, Arizona • Aurora, Colorado • Pueblo, Colorado + 13 more

Conditions: Esophageal Squamous Cell Carcinoma
Interventions: Nivolimumab+Carboplatin/paclitaxel+Radiation; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 5
States / cities: La Jolla, California • Los Angeles, California • New York, New York + 1 more

Conditions: Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms, Endometrial Neoplasms, Esophageal Neoplasms, Gastroesophageal Junction Carcinoma, Stomach Neoplasms, Colorectal Neoplasms, Exocrine Pancreatic Adenocarcinoma, Appendiceal Adenocarcinoma, Pseudomyxoma Peritonei
Interventions: SGN-STNV; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Gainesville, Florida + 8 more

Conditions: Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
Interventions: Pembrolizumab, Sacituzumab Tirumotecan (sac-TMT), Capecitabine, Leucovorin, Levoleucovorin, 5-Fluorouracil (5-FU), Oxaliplatin, Patritumab Deruxtecan; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 8
States / cities: Tucson, Arizona • Los Angeles, California • Louisville, Kentucky + 5 more

Conditions: Breast Cancer, Colorectal Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer, Acral Lentiginous Melanoma, Head and Neck Squamous Cell Carcinoma, Hepatocellular Carcinoma, Esophageal Squamous Cell Carcinoma, Urothelial Carcinoma, DMMR Colorectal Cancer, MSI-H Colorectal Cancer, Melanoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer
Interventions: ATRC-101, Pembrolizumab, Pegylated liposomal doxorubicin (PLD); Biological · Drug
Lead sponsor: Atreca, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 19
States / cities: Phoenix, Arizona • Tucson, Arizona • Duarte, California + 15 more

Search by objective public record fields.

Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer

A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

Irinotecan in Treating Patients With Advanced Cancer of the Stomach

Pemetrexed, Cisplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer

Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Irinotecan and Capecitabine in Treating Patients With Solid Tumors

Trial of Panitumumab/Cisplatin/Fluorouracil Combined With Radiation in Esophageal Cancer

Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer

LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma

Irinotecan, Radiation Therapy, and Docetaxel With or Without Cisplatin in Treating Patients With Locally Advanced Esophageal Cancer

Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer

Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

Cisplatin and Irinotecan in Treating Patients With Locally Advanced or Metastatic Esophageal or Gastric Cancer

Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma

A Study of SGN-STNV in Advanced Solid Tumors

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies